TeloView® is the core of our proprietary technology and it consists of two parts, analytical software and a corresponding report designed for clinical decision making.

Our software was developed internally by Telo Genomics and then scaled and validated by CIMTEC, a respected Canadian imaging-software developer.

TeloView® utilizes the 3-dimensional analysis of 6 key parameters generated from the telomeres of a single cell. Multiple cells from an individual patient are independently analyzed.
TeloView®’s software generates a report for the clinician that contains important, actionable information including; the stage of a given disease, it’s rate of progression and how it will respond to therapy.

TeloView® is effective on any tissue type, but is focused on non-invasive applications
such as liquid biopsy (blood, urine, saliva etc.).

Non-invasive sampling methods are fast, relatively inexpensive and reproducible compared to tissue biopsies and can be used more frequently for the monitoring of patients. It involves the collection of circulating tumor cells (CTC’s), circulating tumor DNA (ctDNA) or other informative marker cells.

TeloView® sits at the end of a multi-step process that gathers and presents target cells in a 3-dimensional format that can be analyzed to generate a TeloView® report.

Sample Accession

Samples (from blood, urine, etc.) are inspected and assigned an ID


3D - Telomere

Specific labeling of telomeres and disease specific proteins with fluorescent tags

3D Image Acquisition

Acquires consecutive images at consecutive focal planes across the depth of the sample to build one 3D image


TeloView® Analysis

1. # of Telomeres
2. Telomere lengths
3. Telomere aggregates
4. a:c Ratio
5. Nuclear volume
6. Position in nucleus

Personalized TeloView® Lab Report

Personalized results that inform and guide treatment


Key Publications with Potential Clinical Relevance

Key publications of interest and with clinical relevance  include Telo Genomics’ lead indication multiple myeloma, Alzheimer’s disease and prostate cancer.

- Tabs contain synopses of the key publications
- Below are the original publications

  • A proof of concept study (Klewes et al., 2013) and validation study (Yu et al., 2019) showing the utility of TeloView® technology to stratify multiple myeloma patients
  • TeloView® technology for multiple myeloma can be conducted on liquid biopsy (blood samples) (Klewes et al., 2013)
  • TeloView® technology utility as a companion diagnostics tool that can potentially predict patient’s drug response (Kashton-Taylor et al., 2017)
  • A proof of concept study (Mathur et al., 2014) and a validation study (Garcia et al., 2017) showing the potential of TeloView® technology to stratify AD patients into their respective clinical disease stage
  • With a 77% prediction power, TeloView® predicts intermediate risk PC patients who require clinical intervention (prostatectomy) versus patients who qualifies for active surveillance (Drachenberg et al., 2019)
  • TeloView® technology for PC can be conducted on liquid biopsies (circulating tumor cells isolated from blood samples) from all patient-risk groups of the disease (Adebayo et al., 2013, Awe et al., 2017)

Advancing risk assessment in intermediate risk prostate cancer patients.
Drachenberg D & Mai S et al. Cancers 11, 855, 2019

Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups.
Adebayo Awe J & Mai S et al. Urol Oncol. 2017 May;35(5):300309

3D telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations.
Awe JA & Mai S et al. Trans. Oncol. 2013 2013 Feb;6(1):51-65.